Salbutamol was the first selective β2-receptor agonist to be marketed in 1968. It was first sold by Allen & Hanburys (UK) under the brand name Ventolin, and has been used for the treatment of asthma ever since. It was approved for use in the US by the FDA in May 1982.
Salbutamol sulfate is sold in the USA as Ventolin HFA, ProAir HFA, or Proventil HFA, and is also available in extended release tablets. It is usually given by the inhaled route for direct effect on bronchial smooth muscle. This is usually achieved through a metered dose inhaler (MDI), nebulizer or other proprietary delivery devices (e.g. Rotahaler or Autohaler). In these forms of delivery, the maximal effect of salbutamol can take place within five to 20 minutes of dosing, though some relief is immediately seen. It can also be given intravenously.
Salbutamol is typically used to treat bronchospasm (due to any cause, allergen asthma or exercise-induced), as well as chronic obstructive pulmonary disease. The dose of salbutamol remains controversial. It is marketed as a metered dose inhaler which produces an average of 90 micrograms per puff. Most commonly only 2 puffs are recommended every 4 hours as needed for symptoms of asthma by the manufacturer. This produces an average dose of 180 micrograms. Emergency medical practice commonly treats patients presenting with asthma who report taking their salbutamol inhaler as prescribed. The Emergency Room treatment recommended is a massive dose of salbutamol given by aerosol nebulization in doses of > 7.5 mg / hour. This is continued until the side effects of tremor or tachycardia become annoying to the patient. In general, patients tolerate this large dose (> 40 times) fairly well. It is logical to recommend that patients consult with a doctor if albuterol does not provide adequate relief, as using more medication may worsen the patient's condition.
Salbutamol has been shown to improve muscle weight in rats  and anecdotal reports hypothesise that it might be an alternative to clenbuterol for purposes of fat burning and muscle gain, with multiple studies supporting this claim. Abuse of the drug may be confirmed by detection of its presence in plasma or urine, typically exceeding 1000 µg/L.
Clinical studies show no compelling evidence that salbutamol and other β2-agonists can increase performance in healthy athletes. In spite of this, salbutamol required "a declaration of Use in accordance with the International Standard for Therapeutic Use Exemptions" under the 2010 WADA prohibited list. This requirement was relaxed when the 2011 list was published to permit the use of "salbutamol (maximum 1600 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regimen." 
According to two small and limited studies, performed on eight and 16 subjects, respectively, salbutamol increases the performance even for a person without asthma.
Another study contradicts the above findings, however. The double blind, randomised test conducted on 12 non-asthmatic athletes concluded that salbutamol had a negligible effect on endurance performance. Nevertheless, the study also showed that the drug's bronchodilating effect may have improved respiratory adaptation at the beginning of exercise.
Detection of use
Salbutamol may be quantified in blood or plasma to confirm a diagnosis of poisoning in hospitalized patients or to aid in a forensic investigation. Urinary salbutamol concentrations are frequently measured in competitive sports programs, for which a level in excess of 1000 μg/L is considered to represent abuse. The window of detection for urine testing is on the order of just 24 hours, given the relatively short elimination half-life of the drug.
(R)-Salbutamol (top) and (S)-salbutamol
The tertiary butyl group in salbutamol (or albuterol) makes it more selective for β₂-receptors. The drug is sold as a racemic mixture mainly because the (S)-enantiomer blocks metabolism pathways while the (R)-enantiomer shows activity.
Salbutamol can be prepared from an acetophenone derivative which is itself derived from salicylic acid (hence the "sal" in salbutamol).
It is marketed by GlaxoSmithKline as Ventolin, Ventoline, Ventilan, Aerolin or Ventorlin, depending on the market; by Cipla as Asthalin and Asthavent; by Schering-Plough as Proventil, by Teva as ProAir, Salamol or Airomir, by Beximco (Bangladesh) as AZMASOL by Ad-din Pharma as Ventosol and by Alphapharm as Asmol.
^Acad Emerg Med. 2003 Jan;10(1):31-6. A randomized, controlled double-blind trial of usual-dose versus high-dose albuterol via continuous nebulization in patients with acute bronchospasm. Stein J, Levitt MA.
^Mahoney, B. A.; Smith, W. A.; Lo, D.; Tsoi, K.; Tonelli, M.; Clase, C. (2005). "Emergency interventions for hyperkalaemia". In Clase, Catherine. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD003235.pub2.edit
^Ahee, P. (2000). "The management of hyperkalaemia in the emergency department". Emergency Medicine Journal17 (3): 188–191. doi:10.1136/emj.17.3.188.edit
^Carter WJ, Lynch ME (September 1994). "Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats". Metab. Clin. Exp.43 (9): 1119–25. doi:10.1016/0026-0495(94)90054-X. PMID7916118.
^Caruso, JF; Signorile, JF; Perry, AC; Leblanc, B; Williams, R; Clark, M; Bamman, MM (1995 Nov). "The effects of albuterol and isokinetic exercise on the quadriceps muscle group.". Medicine and science in sports and exercise27 (11): 1471–6. PMID8587482.Cite uses deprecated parameters (help);Check date values in: |date= (help)
^Caruso, J. (20 January 2005). "Albuterol aids resistance exercise in reducing unloading-induced ankle extensor strength losses". Journal of Applied Physiology98 (5): 1705–1711. doi:10.1152/japplphysiol.01015.2004.
^Caruso, John F.; Hamill, John L.; De Garmo, Nicole (2005). "Oral Albuterol Dosing During the Latter Stages of a Resistance Exercise Program". The Journal of Strength and Conditioning Research19 (1): 102. doi:10.1519/R-14793.1.Cite uses deprecated parameters (help)
^Caruso, JF; Hamill, JL; De Garmo, N (2005 Feb). "Oral albuterol dosing during the latter stages of a resistance exercise program.". Journal of strength and conditioning research / National Strength & Conditioning Association19 (1): 102–7. PMID15705021.Cite uses deprecated parameters (help);Check date values in: |date= (help)
^ abBaselt, R. (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Biomedical Publications,. pp. 33–35. ISBN0-9626523-6-9.
^Van Baak, MA; De Hon, OM; Hartgens, F; Kuipers, H (2004). "Inhaled salbutamol and endurance cycling performance in non-asthmatic athletes". International journal of sports medicine25 (7): 533–8. doi:10.1055/s-2004-815716. PMID15459835.
^Collin, David T.; Hartley, David.; Jack, David.; Lunts, Lawrence H. C.; Press, J. C.; Ritchie, Alexander C.; Toon, Paul. (1970). "Saligenin analogs of sympathomimetic catechol amines". Journal of Medicinal Chemistry13 (4): 674–80. doi:10.1021/jm00298a022. PMID5452431.
Caruso, JF; Hamill, JL; De Garmo, N (February 2005). "Oral albuterol dosing during the latter stages of a resistance exercise program". J Strength Cond Res19 (1): 102–7. doi:10.1519/R-14793.1. PMID15705021.
Caruso JF, Signorile JF, Perry AC, et al. (November 1995). "The effects of albuterol and isokinetic exercise on the quadriceps muscle group". Med Sci Sports Exerc27 (11): 1471–6. PMID8587482.
Martineau, L; Horan, MA; Rothwell, NJ; Little, RA (November 1992). "Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men". Clin. Sci.83 (5): 615–21. PMID1335400.S